AbCellera Biologics (ABCL) Equity Average (2021 - 2025)
Historic Equity Average for AbCellera Biologics (ABCL) over the last 5 years, with Q3 2025 value amounting to $985.6 million.
- AbCellera Biologics' Equity Average fell 995.62% to $985.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $985.6 million, marking a year-over-year decrease of 995.62%. This contributed to the annual value of $1.1 billion for FY2024, which is 742.76% down from last year.
- Per AbCellera Biologics' latest filing, its Equity Average stood at $985.6 million for Q3 2025, which was down 995.62% from $1.0 billion recorded in Q2 2025.
- Over the past 5 years, AbCellera Biologics' Equity Average peaked at $1.2 billion during Q4 2022, and registered a low of $893.8 million during Q1 2021.
- For the 5-year period, AbCellera Biologics' Equity Average averaged around $1.1 billion, with its median value being $1.1 billion (2022).
- Its Equity Average has fluctuated over the past 5 years, first soared by 2821.09% in 2022, then tumbled by 995.62% in 2025.
- Over the past 5 years, AbCellera Biologics' Equity Average (Quarter) stood at $989.6 million in 2021, then rose by 25.48% to $1.2 billion in 2022, then decreased by 5.97% to $1.2 billion in 2023, then decreased by 8.6% to $1.1 billion in 2024, then fell by 7.64% to $985.6 million in 2025.
- Its last three reported values are $985.6 million in Q3 2025, $1.0 billion for Q2 2025, and $1.0 billion during Q1 2025.